106 related articles for article (PubMed ID: 20632198)
1. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells.
Maruyama T; Higuchi Y; Suzuki T; Qiu J; Yamamoto S; Shima H
J Infect Chemother; 2011 Feb; 17(1):11-6. PubMed ID: 20632198
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
Li Q; Xu T; Wang XF
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer.
Chen G; He Y; Wu X; Zhang Y; Luo C; Jing P
Braz J Med Biol Res; 2012 Aug; 45(8):771-6. PubMed ID: 22782557
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
5. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
[TBL] [Abstract][Full Text] [Related]
6. [Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor].
Kobayashi M; Sugaya Y; Yuzawa M; Ochi M; Morita T; Kobayashi Y; Tokue A; Hara Y
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1771-4. PubMed ID: 9757205
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis of bladder cancer by sodium butyrate and cisplatin.
Maruyama T; Yamamoto S; Qiu J; Ueda Y; Suzuki T; Nojima M; Shima H
J Infect Chemother; 2012 Jun; 18(3):288-95. PubMed ID: 22041988
[TBL] [Abstract][Full Text] [Related]
8. [A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
Hashimura T; Shirahase T; Inoue T; Yamasaki T; Terada N; Ogura K; Arai Y; Hida S; Ueda T
Hinyokika Kiyo; 2005 Jul; 51(7):439-42. PubMed ID: 16119805
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
Ren L; Yang X; Zhao L; Zhang H; Wang J
Integr Cancer Ther; 2016 Mar; 15(1):80-6. PubMed ID: 26315609
[TBL] [Abstract][Full Text] [Related]
10. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.
Kamat AM; DeHaven JI; Lamm DL
Urology; 1999 Jul; 54(1):56-61. PubMed ID: 10414727
[TBL] [Abstract][Full Text] [Related]
11. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
[TBL] [Abstract][Full Text] [Related]
12. [Postoperative intravesical instillation of THP for superficial bladder tumor: clinical results of prophylactic effects on the recurrence. Fukushima THP Research Group].
Aikawa K; Irisawa C; Muraki O; Yamaguchi O; Shiraiwa Y; Noguchi M; Koguchi M; Yokoyama J; Ito K; Kumakawa K
Gan To Kagaku Ryoho; 1992 Apr; 19(4):509-13. PubMed ID: 1558401
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of intracellular concentration and duration of contamination of pirarubicin and adriamycin in human bladder cancer cell lines and human bladder normal mucosa cell line].
Saika T; Tsushima T; Nasu Y; Akebi N; Ohmori H
Gan To Kagaku Ryoho; 1996 Jun; 23(7):905-9. PubMed ID: 8678540
[TBL] [Abstract][Full Text] [Related]
14. [A randomized study of pirarubicin (THP) versus adriamycin (ADM) for intravesical instillation therapy against superficial bladder cancer].
Kawamura J; Tochigi H; Obata K; Ueda K; Otaguro K; Kuriyama M; Shinoda M; Naruse K; Murase T; Hasegawa Y
Hinyokika Kiyo; 1992 Mar; 38(3):379-85. PubMed ID: 1523998
[TBL] [Abstract][Full Text] [Related]
15. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
17. [Short-duration bladder instillation therapy with pirarubicin for superficial bladder tumor based on pharmacodynamic study].
Nakagawa S; Kojima M; Takada H; Sugimoto K; Mikami K; Watanabe H
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1873-7. PubMed ID: 1519929
[TBL] [Abstract][Full Text] [Related]
18. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical chemotherapy of (2''R)-4'-O-tetrahydropyranyladriamycin in bladder tumor].
Masuda H; Hirose J; Suzuki K; Tajima A; Aso Y
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2411-4. PubMed ID: 3729494
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of retention time of intravesical instillation therapy with pirarubicin (THP)].
Sugano O; Shoji N; Hatakeyama T; Kato H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1169-74. PubMed ID: 8751805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
